A Phase 4 interventional study of Restasis and Endura in Disease Progression, Disease Severity and Staining, sponsored by Innovative Medical. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2008-09-25.
Sponsored by Innovative Medical · Phase 4, Interventional, and Treatment
The purpose of this study is to evaluate the effect Restasis has in regards to disease progression.
544 studies on the registry are indexed under Disease Progression; 144 are open to participants now.
This study's planned enrollment of 80 is close to the median of 87 across 266 interventional studies indexed under Disease Progression.
Browse Disease Progression studies →Innovative Medical is the lead sponsor of 50 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: Restasis
Drug: Endura
Restasis- (in the eye) Instill one drop twice daily Endura- (in the eye) Instill one drop twice daily
Restasis- (in the eye) Instill one drop twice daily Endura- (in the eye) Instill one drop twice daily
Disease Severity
Time frame: 1 yr
Staining
Time frame: 1 yr
This study is completed, as verified in Sep 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Innovative Medical